Scholarlink

<p>Increasing evidences demonstrate that mitochondrial function is essential for cancer cell survival and metastasis. However, the role of mitochondrial metabolic reprogramming in ovarian cancer progression remains largely unknown. Here, we report that mitochondrial chaperone <i>BCS1L</i> generates two major alternative-spliced isoforms, a full-length isoform (<i>BCS1L-L</i>) and a short isoform lacking exon 2 (<i>BCS1L-S</i>). Interestingly, <i>BCS1L-L</i> is elevated in several human cancers, and it significantly increased oxidative phosphorylation and ATP production in the present work, which is required for the survival of cancer cells. In contrast, BCS1L-S was unable to localize to the mitochondria as BCS1L-L did, and this led to impaired metabolic function. Mechanistically, splicing factor <i>USP39</i> promoted exon 2 inclusion, thus facilitating the generation of oncogenic <i>BCS1L-L</i> and, thereby, maintaining mitochondrial homeostasis and survival of ovarian cancer cells. Importantly, we developed splice-switch antisense oligonucleotides (ASOs) that successfully induced exon 2 skipping and decreased <i>BCS1L-L</i> abundance, resulting in impaired tumor growth. These findings suggest that targeting oncogenic <i>BCS1L-L</i> by ASOs is a novel approach for ovarian cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Meining Xu,
  • Zixiang Wang,
  • Siyuan Yang,
  • Gaoyuan Li,
  • Xiyu Zhang,
  • Ling Zhao,
  • Lei Yang,
  • Chunhong Qiu,
  • Xianguang Feng,
  • Kai Zhang,
  • Bin Liu,
  • Jian-jun Wei,
  • Yuliang Li,
  • Gang Liu,
  • Baoxia Cui,
  • Junchao Qin,
  • Zhaojian Liu

摘要

Increasing evidences demonstrate that mitochondrial function is essential for cancer cell survival and metastasis. However, the role of mitochondrial metabolic reprogramming in ovarian cancer progression remains largely unknown. Here, we report that mitochondrial chaperone BCS1L generates two major alternative-spliced isoforms, a full-length isoform (BCS1L-L) and a short isoform lacking exon 2 (BCS1L-S). Interestingly, BCS1L-L is elevated in several human cancers, and it significantly increased oxidative phosphorylation and ATP production in the present work, which is required for the survival of cancer cells. In contrast, BCS1L-S was unable to localize to the mitochondria as BCS1L-L did, and this led to impaired metabolic function. Mechanistically, splicing factor USP39 promoted exon 2 inclusion, thus facilitating the generation of oncogenic BCS1L-L and, thereby, maintaining mitochondrial homeostasis and survival of ovarian cancer cells. Importantly, we developed splice-switch antisense oligonucleotides (ASOs) that successfully induced exon 2 skipping and decreased BCS1L-L abundance, resulting in impaired tumor growth. These findings suggest that targeting oncogenic BCS1L-L by ASOs is a novel approach for ovarian cancer treatment.